NO20055848L - Nye spacer-enheter for poly(etylenglykol)-modifiserte peptidbaserte forbindelser - Google Patents

Nye spacer-enheter for poly(etylenglykol)-modifiserte peptidbaserte forbindelser

Info

Publication number
NO20055848L
NO20055848L NO20055848A NO20055848A NO20055848L NO 20055848 L NO20055848 L NO 20055848L NO 20055848 A NO20055848 A NO 20055848A NO 20055848 A NO20055848 A NO 20055848A NO 20055848 L NO20055848 L NO 20055848L
Authority
NO
Norway
Prior art keywords
unit
poly
ethylene glycol
based compounds
modified peptide
Prior art date
Application number
NO20055848A
Other languages
English (en)
Inventor
Christopher P Holmes
Kevin Yin
David Tumelty
Original Assignee
Affymax Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Affymax Inc filed Critical Affymax Inc
Publication of NO20055848L publication Critical patent/NO20055848L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/524—Thrombopoietin, i.e. C-MPL ligand
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/505—Erythropoietin [EPO]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Polyamides (AREA)

Abstract

Den forehggende oppfinnelsen vedrører en forbindelse som omfatter en peptidenhet, en spacerenhet og en vannløselig polymerenhet slik som en poly(etylenglykol)enhet. Spacerenheten er mellom peptidenheten og den vannløselige polymerenheten. Spacerenheten har strukturen: -NH-(CH2)¿-[0-(CH2)p],-05-(CH2).-Y- hvor a, p, y, 8 og s er hver hele tall hvis verdi er uavhengig valgt.
NO20055848A 2003-05-12 2005-12-09 Nye spacer-enheter for poly(etylenglykol)-modifiserte peptidbaserte forbindelser NO20055848L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US46999603P 2003-05-12 2003-05-12
PCT/US2004/014887 WO2004100997A2 (en) 2003-05-12 2004-05-12 Spacer moiety for poly(ethylene glycol) -modified peptides

Publications (1)

Publication Number Publication Date
NO20055848L true NO20055848L (no) 2006-02-13

Family

ID=33452348

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20055848A NO20055848L (no) 2003-05-12 2005-12-09 Nye spacer-enheter for poly(etylenglykol)-modifiserte peptidbaserte forbindelser

Country Status (16)

Country Link
US (2) US7919118B2 (no)
EP (2) EP1628686A2 (no)
JP (2) JP2007500218A (no)
KR (1) KR101160611B1 (no)
CN (1) CN1849141A (no)
AU (1) AU2004238364A1 (no)
BR (1) BRPI0411166A (no)
CA (1) CA2525399A1 (no)
EA (1) EA010015B1 (no)
IL (1) IL171885A0 (no)
IS (1) IS8168A (no)
MX (1) MXPA05012314A (no)
NO (1) NO20055848L (no)
NZ (2) NZ543934A (no)
WO (1) WO2004100997A2 (no)
ZA (1) ZA200509970B (no)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7259146B2 (en) 2000-05-26 2007-08-21 Ortho-Mcneil Pharmaceutical, Inc. Neuroprotective peptides
US8663650B2 (en) * 2003-02-21 2014-03-04 Ac Immune Sa Methods and compositions comprising supramolecular constructs
KR101163683B1 (ko) * 2003-05-12 2012-07-10 아피맥스, 인크. 에리스로포이에틴 수용체에 결합하는 신규의 펩티드
JP2007530440A (ja) * 2003-05-12 2007-11-01 アフィーマックス・インコーポレイテッド 新規ポリ（エチレングリコール）修飾化合物およびその用途
PL1625156T3 (pl) 2003-05-12 2013-03-29 Affymax Inc Peptydy wiążące się do receptora erytropoetyny
CN1849141A (zh) 2003-05-12 2006-10-18 阿费麦克斯公司 用于聚(乙二醇)修饰的肽的间隔臂部分
US20080026995A1 (en) * 2003-07-25 2008-01-31 Ac Immune Sa Therapeutic vaccine targeted against p-glycoprotein 170 for inhibiting multidrug resistance in the treatment of cancers
FR2857875A1 (fr) * 2003-07-25 2005-01-28 Univ Reims Champagne Ardenne Vaccin therapeutique cible contre la p-glycoproteine 170 pour inhiber la resistance multidrogues dans le traitement des cancers
US7807171B2 (en) 2003-07-25 2010-10-05 Ac Immune Sa Therapeutic vaccine targeted against P-glycoprotein 170 for inhibiting multidrug resistance in the treatment of cancers
WO2005046722A2 (en) * 2003-11-05 2005-05-26 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Carbohydrate antigen-nanoparticle conjugates and uses thereof as antimetastatic agents in treating cancer
US7589063B2 (en) 2004-12-14 2009-09-15 Aplagen Gmbh Molecules which promote hematopoiesis
US7550433B2 (en) 2005-06-03 2009-06-23 Affymax, Inc. Erythropoietin receptor peptide formulations and uses
EP2035041B1 (en) 2006-06-30 2020-01-08 Syntab Therapeutics GmbH Conjugates for innate immunotherapy of cancer
WO2008100288A2 (en) * 2006-09-15 2008-08-21 The Burnham Institute High affinity ephb receptor binding compounds and methods of use thereof
US8106154B2 (en) * 2007-01-31 2012-01-31 Affymax, Inc. Nitrogen-based linkers for attaching modifying groups to polypeptides and other macromolecules
JP2010527989A (ja) * 2007-05-25 2010-08-19 ネウトロン リミテッド 半減期が延長されたｃｒｆ複合体
WO2009002947A2 (en) * 2007-06-22 2008-12-31 Affymax, Inc. Compounds and peptides that bind the trail receptor
CN101143894A (zh) * 2007-06-22 2008-03-19 中国药科大学 高效抑制血管生成多肽及其物理化学修饰方法和应用
EP2018835B1 (de) 2007-07-09 2014-03-05 Augustinus Bader Wirkstoff abgebendes Pflaster
WO2009058291A2 (en) * 2007-10-31 2009-05-07 University Of Alabama In Huntsville Controlled molecular weight amino acid polymers having functionalizable backbones and end groups and processes for preparing the same
RS52417B (sr) * 2007-12-20 2013-02-28 Merck Serono S.A. Formulacije peg-interferona-beta
AU2009241813A1 (en) * 2008-04-30 2009-11-05 Neutron Row Methods of using corticotropin-releasing factor for the treatment of cancer
UA103104C2 (ru) 2009-07-22 2013-09-10 Ипсен Фарма С.А.С. Аналоги инсулиноподобного фактора роста-1 (igf-1), содержащие аминокислотную замену в положении 59
WO2011011073A1 (en) * 2009-07-22 2011-01-27 Ipsen Pharma S.A.S. Site-specific pegylated or site-specific lipidated igf-1 and analogues of igf-1
WO2011098095A1 (en) 2010-02-09 2011-08-18 Aplagen Gmbh Peptides binding the tpo receptor
WO2012003960A1 (en) 2010-07-06 2012-01-12 Augustinus Bader Topical application of erythropoietin for the treatment of eye disorders and injuries
WO2012020124A1 (en) 2010-08-12 2012-02-16 Ac Immune S.A. Vaccine engineering
EP2632434B1 (en) 2010-10-26 2025-08-20 AC Immune S.A. Liposome-based construct comprising a peptide modified through hydrophobic moieties
US9463255B1 (en) * 2011-09-29 2016-10-11 Stc.Unm Radiolabeled alpha-melanocyte stimulating hormone hybrid peptide for melanoma targeting
WO2015038938A1 (en) 2013-09-13 2015-03-19 The California Institute For Biomedical Research Modified therapeutic agents and compositions thereof
US10039809B2 (en) 2013-12-18 2018-08-07 The California Institute For Biomedical Research Modified therapeutic agents, stapled peptide lipid conjugates, and compositions thereof
EP3310376A4 (en) * 2015-06-17 2019-01-23 The California Institute for Biomedical Research MODIFIED THERAPEUTIC AGENTS AND COMPOSITIONS THEREOF
GB201609083D0 (en) 2016-05-24 2016-07-06 Syntab Therapeutics Gmbh Synthetic compound
KR102142978B1 (ko) * 2017-12-18 2020-08-11 경희대학교 산학협력단 신규 페길화 서브스턴스 ｐ
EP3572434B1 (en) 2018-05-25 2022-08-17 UPM-Kymmene Corporation Nanofibrillar cellulose hydrogel
EP4069726A4 (en) 2019-12-04 2024-03-20 The Scripps Research Institute GLP2 RECEPTOR AGONISTS AND METHOD OF USE
AU2022289610A1 (en) 2021-06-09 2024-01-25 The Scripps Research Institute Long-acting dual gip/glp-1 peptide conjugates and methods of use
WO2025262329A1 (en) 2024-06-21 2025-12-26 Syntab Therapeutics Gmbh Synthetic molecules comprising tlr2 ligands

Family Cites Families (86)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) * 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
NZ210501A (en) 1983-12-13 1991-08-27 Kirin Amgen Inc Erythropoietin produced by procaryotic or eucaryotic expression of an exogenous dna sequence
KR850004274A (ko) 1983-12-13 1985-07-11 원본미기재 에리트로포이에틴의 제조방법
US4677195A (en) 1985-01-11 1987-06-30 Genetics Institute, Inc. Method for the purification of erythropoietin and erythropoietin compositions
US4925673A (en) 1986-08-18 1990-05-15 Clinical Technologies Associates, Inc. Delivery systems for pharmacological agents encapsulated with proteinoids
US5006333A (en) 1987-08-03 1991-04-09 Ddi Pharmaceuticals, Inc. Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols
US5080891A (en) 1987-08-03 1992-01-14 Ddi Pharmaceuticals, Inc. Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols
EP0401384B1 (en) 1988-12-22 1996-03-13 Kirin-Amgen, Inc. Chemically modified granulocyte colony stimulating factor
WO1990008822A1 (en) 1989-02-03 1990-08-09 Genetics Institute, Inc. Erythropoietin receptor
US5166322A (en) 1989-04-21 1992-11-24 Genetics Institute Cysteine added variants of interleukin-3 and chemical modifications thereof
DK0400472T3 (da) 1989-05-27 1996-05-13 Sumitomo Pharma Fremgangsmåde til fremstilling af polyethylenglycolderivater og modificeret protein
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5292654A (en) 1990-12-13 1994-03-08 Whitehead Institute For Biomedical Research Mutant EPO receptor and uses therefor
AU1674292A (en) 1991-03-15 1992-10-21 Synergen, Inc. Pegylation of polypeptides
JP3507486B2 (ja) 1991-03-15 2004-03-15 アムジエン・インコーポレーテツド 顆粒球コロニー刺激因子の肺内投与
AU1676992A (en) * 1991-03-18 1992-10-21 Enzon, Inc. Hydrazine containing conjugates of polypeptides and glycopolypeptides with polymers
US5614184A (en) 1992-07-28 1997-03-25 New England Deaconess Hospital Recombinant human erythropoietin mutants and therapeutic methods employing them
US6153407A (en) 1992-07-28 2000-11-28 Beth Israel Deaconess Medical Center Erythropoietin DNA having modified 5' and 3' sequences and its use to prepare EPO therapeutics
US5919455A (en) * 1993-10-27 1999-07-06 Enzon, Inc. Non-antigenic branched polymer conjugates
US5830851A (en) 1993-11-19 1998-11-03 Affymax Technologies N.V. Methods of administering peptides that bind to the erythropoietin receptor
US5773569A (en) 1993-11-19 1998-06-30 Affymax Technologies N.V. Compounds and peptides that bind to the erythropoietin receptor
US5580853A (en) 1994-03-22 1996-12-03 New England Deaconess Hospital Modified polypeptides with increased biological activity
US5919758A (en) 1994-03-22 1999-07-06 Beth Israel Deaconess Medical Center Modified polypeptides with altered biological activity
US5747446A (en) 1994-03-22 1998-05-05 Beth Israel Deaconess Medical Center Modified polypeptides with increased biological activity
US5451569A (en) 1994-04-19 1995-09-19 Hong Kong University Of Science And Technology R & D Corporation Limited Pulmonary drug delivery system
JP2763020B2 (ja) 1995-04-27 1998-06-11 日本電気株式会社 半導体パッケージ及び半導体装置
US5668110A (en) 1995-06-07 1997-09-16 Affymax Technologies N.V. Peptides and compounds that bind to the IL-5 receptor
US5767078A (en) 1995-06-07 1998-06-16 Johnson; Dana L. Agonist peptide dimers
US5654276A (en) 1995-06-07 1997-08-05 Affymax Technologies N.V. Peptides and compounds that bind to the IL-5 receptor
US5683983A (en) 1995-06-07 1997-11-04 Glaxo Group Limited Peptides and compounds that bind to the IL-5 receptor
CN1966520B (zh) 1995-06-07 2012-07-11 葛兰素集团有限公司 结合血小板生成素受体的肽和化合物
US6251864B1 (en) 1995-06-07 2001-06-26 Glaxo Group Limited Peptides and compounds that bind to a receptor
US5677280A (en) 1995-06-07 1997-10-14 Glaxo Group Limited Peptides and compounds that bind to the IL-5 receptor
AU6046696A (en) * 1995-06-07 1996-12-30 Glaxo Group Limited Peptides and compounds that bind to a receptor
US5869451A (en) * 1995-06-07 1999-02-09 Glaxo Group Limited Peptides and compounds that bind to a receptor
BR9609006A (pt) 1995-06-07 1999-12-14 Ortho Pharma Corp Peptìdeo, composição farmacêutica, e, processo para tratamento dse paciente.
US5891418A (en) * 1995-06-07 1999-04-06 Rhomed Incorporated Peptide-metal ion pharmaceutical constructs and applications
US5672662A (en) 1995-07-07 1997-09-30 Shearwater Polymers, Inc. Poly(ethylene glycol) and related polymers monosubstituted with propionic or butanoic acids and functional derivatives thereof for biotechnical applications
US6346390B1 (en) 1996-03-08 2002-02-12 Receptron, Inc. Receptor derived peptides involved in modulation of response to ligand binding
US6103879A (en) 1996-06-21 2000-08-15 Axys Pharmaceuticals, Inc. Bivalent molecules that form an activating complex with an erythropoietin receptor
EP1731174A3 (en) 1996-08-02 2007-01-17 Ortho-McNeil Pharmaceutical, Inc. Polypeptides having a covalently bound N-terminal polyethylene glycol via hydrazone or oxime bond
US5932546A (en) 1996-10-04 1999-08-03 Glaxo Wellcome Inc. Peptides and compounds that bind to the thrombopoietin receptor
US6221608B1 (en) 1997-01-22 2001-04-24 Ortho Pharmaceutical Corporation Methods for identifying erythropoietin receptor binding protein
US6211608B1 (en) 1998-06-11 2001-04-03 Micron Technology, Inc. Field emission device with buffer layer and method of making
PL202799B1 (pl) 1998-08-06 2009-07-31 Mountain View Pharmaceuticals Sposób izolowania urykazy w postaci tetramerycznej oraz wyizolowana tetrameryczna urykaza
US6783965B1 (en) 2000-02-10 2004-08-31 Mountain View Pharmaceuticals, Inc. Aggregate-free urate oxidase for preparation of non-immunogenic polymer conjugates
ATE298251T1 (de) 1998-08-06 2005-07-15 Mountain View Pharmaceuticals Peg-uricase konjugate und verwendung davon
EP1008355A1 (en) 1998-12-08 2000-06-14 Debio Recherche Pharmaceutique S.A. Method for identifying or analyzing polymer linkage sites on macromolecules using amino acid report binding
DE69914611T2 (de) 1998-08-28 2004-12-23 Gryphon Therapeutics, Inc., South San Francisco Verfahren zur herstellung von polyamidketten von genauer länge und deren konjugate mit proteinen
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
ATE348163T1 (de) * 1998-10-23 2007-01-15 Amgen Inc Thrombopoietin substitute
EP1133291B1 (en) 1998-11-17 2006-01-11 Smithkline Beecham Corporation Cyclic polyamines for treating thrombocytopenia
JP2002534363A (ja) * 1999-01-08 2002-10-15 エミスフェアー・テクノロジーズ・インク ポリマー性デリバリー剤及びデリバリー剤化合物
PE20010288A1 (es) 1999-07-02 2001-03-07 Hoffmann La Roche Derivados de eritropoyetina
CZ299516B6 (cs) 1999-07-02 2008-08-20 F. Hoffmann-La Roche Ag Konjugát erythropoetinového glykoproteinu, zpusobjeho výroby a použití a farmaceutická kompozice sjeho obsahem
AUPQ873300A0 (en) 2000-07-12 2000-08-03 Medvet Science Pty. Ltd. A binding motif of a receptor (2)
AU771460B2 (en) 1999-09-24 2004-03-25 Smithkline Beecham Corporation Thrombopoietin mimetics
EP1221482B1 (en) 1999-09-27 2005-12-28 Chugai Seiyaku Kabushiki Kaisha Hemopoietin receptor protein, nr12
US6703480B1 (en) * 1999-11-24 2004-03-09 Palani Balu Peptide dimers as agonists of the erythropoientin (EPO) receptor, and associated methods of synthesis and use
US6858630B2 (en) 1999-12-06 2005-02-22 Smithkline Beecham Corporation Naphthimidazole derivatives and their use as thrombopoietin mimetics
US20030125262A1 (en) 2000-03-21 2003-07-03 Wisconsin Alumni Research Foundation Methods and reagents for regulation of cellular responses in biological systems
US6777387B2 (en) * 2000-03-31 2004-08-17 Enzon Pharmaceuticals, Inc. Terminally-branched polymeric linkers containing extension moieties and polymeric conjugates containing the same
EP1149906A1 (en) * 2000-04-25 2001-10-31 Pliva, Farmaceutska, Industrija, Dionicko Drustvo Thrombopoietin receptor modulating peptide
MEP90708A (hr) 2000-05-15 2011-12-20 Nova farmaceutska smješa
MXPA02011727A (es) * 2000-05-26 2003-10-24 Johnson & Johnson Peptidos neuroprotectores.
EP1325324A4 (en) 2000-08-02 2004-11-10 Ortho Mcneil Pharm Inc IMPROVED ANTIVIRAL AND ANTI-CANCER CHEMOTHERAPY USING ERYTHROPOIETIN ADMINISTRATION (EPO)
US20030191291A1 (en) 2000-09-08 2003-10-09 Kochendoerfer Gerd G. Synthetic erythropoiesis stimulating proteins
AU3323002A (en) 2000-12-20 2002-07-01 Hoffmann La Roche Erythropoietin conjugates
US6531121B2 (en) 2000-12-29 2003-03-11 The Kenneth S. Warren Institute, Inc. Protection and enhancement of erythropoietin-responsive cells, tissues and organs
US7767643B2 (en) 2000-12-29 2010-08-03 The Kenneth S. Warren Institute, Inc. Protection, restoration, and enhancement of erythropoietin-responsive cells, tissues and organs
EP1362053B1 (en) * 2001-02-20 2007-11-14 Enzon, Inc. Terminally-branched polymeric linkers and polymeric conjugates containing the same
FR2823220B1 (fr) 2001-04-04 2003-12-12 Genodyssee Nouveaux polynucleotides et polypeptides de l'erythropoietine (epo)
US20020169128A1 (en) 2001-04-09 2002-11-14 Geroge Sigounas Erythropoietin ameliorates chemotherapy-induced toxicity in vivo
ATE414711T1 (de) 2001-06-28 2008-12-15 Mountain View Pharmaceuticals Polymerstabilisierte proteinasen
US6784154B2 (en) 2001-11-01 2004-08-31 University Of Utah Research Foundation Method of use of erythropoietin to treat ischemic acute renal failure
US7122189B2 (en) * 2002-08-13 2006-10-17 Enzon, Inc. Releasable polymeric conjugates based on aliphatic biodegradable linkers
US7087229B2 (en) * 2003-05-30 2006-08-08 Enzon Pharmaceuticals, Inc. Releasable polymeric conjugates based on aliphatic biodegradable linkers
US20050176627A1 (en) 2002-09-09 2005-08-11 Anthony Cerami Long acting erythropoietins that maintain tissue protective activity of endogenous erythropoietin
US20040062748A1 (en) 2002-09-30 2004-04-01 Mountain View Pharmaceuticals, Inc. Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof
US8129330B2 (en) 2002-09-30 2012-03-06 Mountain View Pharmaceuticals, Inc. Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof
GEP20084486B (en) 2002-12-26 2008-09-25 Mountain View Pharmaceuticals Polymer conjugates of interferon-beta with enhanced biological potency
RS20050501A (sr) 2002-12-26 2007-08-03 Mountain View Pharmaceuticals Inc., Polimerni konjugati citokina,hemokina,faktora rasta, polipeptidnih hormona i njihovih antagonista sa očuvanom aktivnošću vezivanja receptora
PL1625156T3 (pl) * 2003-05-12 2013-03-29 Affymax Inc Peptydy wiążące się do receptora erytropoetyny
KR101163683B1 (ko) * 2003-05-12 2012-07-10 아피맥스, 인크. 에리스로포이에틴 수용체에 결합하는 신규의 펩티드
CN1849141A (zh) 2003-05-12 2006-10-18 阿费麦克斯公司 用于聚(乙二醇)修饰的肽的间隔臂部分
JP2007530440A (ja) * 2003-05-12 2007-11-01 アフィーマックス・インコーポレイテッド 新規ポリ（エチレングリコール）修飾化合物およびその用途

Also Published As

Publication number Publication date
KR20060023123A (ko) 2006-03-13
US20070032408A1 (en) 2007-02-08
ZA200509970B (en) 2006-11-29
WO2004100997A3 (en) 2005-05-19
EP2204193A2 (en) 2010-07-07
KR101160611B1 (ko) 2012-06-28
CN1849141A (zh) 2006-10-18
IS8168A (is) 2005-12-02
EP1628686A2 (en) 2006-03-01
JP2007500218A (ja) 2007-01-11
US20120115796A1 (en) 2012-05-10
EA200501800A1 (ru) 2006-08-25
NZ543934A (en) 2008-06-30
CA2525399A1 (en) 2004-11-25
EA010015B1 (ru) 2008-06-30
AU2004238364A1 (en) 2004-11-25
BRPI0411166A (pt) 2006-07-18
US8592365B2 (en) 2013-11-26
IL171885A0 (en) 2006-04-10
JP2012140466A (ja) 2012-07-26
NZ563042A (en) 2008-09-26
US7919118B2 (en) 2011-04-05
MXPA05012314A (es) 2006-04-18
EP2204193A3 (en) 2010-08-18
WO2004100997A2 (en) 2004-11-25

Similar Documents

Publication Publication Date Title
MXPA05012314A (es) Radical separador para peptido modificado con polietilenglicol.
NO20051077L (no) Vannloselige polymeralkanaler
NO20052089L (no) Polymerkonjugater med redusert antigenisitet, fremgangsmater for fremstillling og anvendelse derav
JP2005532419A5 (no)
EP2289567A3 (en) Matrix comprising naturally-occurring crosslinked protein backbone
DE60139683D1 (de) Verbindung enthaltend vernetzte polyrotaxane
DK1675813T3 (da) Fremgangsmåde til fremstilling af para-phenylalkynylbenzaldehyder
ATE499121T1 (de) Viskoelastische lösungen mit natriumhyaluronat und hydroxypropylmethylcellulose, herstellung und verwendungen
BRPI0908439B8 (pt) sistema de implante mamário
HRP20030383B1 (hr) Laktamski spoj
NO20054083L (no) Nye sammenkoblede triazoloner og deres anvendelse
DK1581271T3 (da) Fotofölsomme, polymere netværk
WO2005072371A3 (en) Branched polymeric sugars and nucleotides thereof
FR2858649B1 (fr) Turbine basse-pression de turbomachine
DE59904114D1 (de) Radialkolbenpumpe für kraftstoffhochdruckerzeugung
DK2263674T3 (da) 10,10-Dialkyl-prostansyrederivater som midler til sænkning af intraokulært tryk
TR201910900T4 (tr) Desferritiyokin polieter analogları.
ATE357133T1 (de) Entlaubungsvorrichtung, insbesondere für weinstöcke
DE60234029D1 (de) Polymer enthaltend substituierte triphenylamin-einheiten
DE60228765D1 (de) Flügelzellenvakuumpumpe
DE602005025355D1 (de) Konjugate enthaltend gm-csf und ein polymer
DK0970273T3 (da) Fremgangsmåde til fremstilling af tæpper, som har påføringer af polyurethan opnået ud fra polyurethanlatex
ATE420901T1 (de) Copolymere mit verzweigten olefineinheiten und vinylethereinheiten
ATE474582T1 (de) Pharmazeutische zusammensetzung enthaltend glucan aus mikroalgen
UY28382A1 (es) Derivados de 2-aminobenzoilo

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application